Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
1.
Reumatol. clín. (Barc.) ; 15(6): 360-362, nov.-dic. 2019. tab
Artículo en Español | IBECS | ID: ibc-189654

RESUMEN

OBJETIVO: Valorar la relación entre la calprotectina fecal, ASCA y marcadores de enfermedad en espondiloartritis (Spa). MÉTODOS: Se evaluaron pacientes ≥18años que cumplían criterios ASAS o criterios modificados de Nueva York. Se analizan criterios de actividad, función física, analíticos y datos demográficos. RESULTADOS: Se incluyeron 33 pacientes. Todos excepto uno tenían valores normales de ASCA. Encontramos correlación significativa entre calprotectina y PCR pero no con otros parámetros, ni entre los niveles de calprotectina y la toma de AINE (p = 0,001). Tampoco entre los niveles de PCR y el uso de AINE. Después de retirar los AINE no encontramos diferencias en los niveles de calprotectina (p = 0,9). CONCLUSIÓN: La calprotectina fecal está elevada en pacientes con Spa y se correlaciona positivamente con la PCR. La elevación de la calprotectina fecal no se ve alterada por el uso de AINE. La cantidad de ASCA no cambia y no se correlaciona con ningún parámetro clínico en el estudio poblacional


OBJECTIVE: To assess the relationship between the increase of fecal calprotectin, anti-Saccharomyces cerevisiae antibodies (ASCA) and disease markers in a group of patients with spondyloarthritis. METHODS: We evaluated patients who were at least 18-years-old and met the Assessment in Spondyloarthritis International Society (ASAS) criteria for spondyloarthritis or the New York modified criteria. We analyzed activity criteria, physical function, analytical criteria (human leukocyte antigen [HLA] B27, fecal calprotectin, presence of ASCA, among others) and demographic data. RESULTS: We included 33 patients. All but one patient had normal ASCA values. We found statistical significance in the correlation of calprotectin with C-reactive protein (CRP) but not with other parameters. We also found a relationship between calprotectin levels and nonsteroidal anti-inflammatory drug (NSAID) intake (P=.001). We found no relationship between CRP levels and NSAID use. After discontinuation of NSAIDs for one month, we found no significant differences in calprotectin levels (P=.9). CONCLUSION: Fecal calprotectin is elevated in patients with spondyloarthritis and correlates positively with CRP. Level of fecal calprotectin is not altered by NSAID use. The amount of ASCA present does not change and does not correlate with any clinical parameters in the study population


Asunto(s)
Humanos , Adulto , Persona de Mediana Edad , Anticuerpos Antifúngicos/sangre , Heces/química , Complejo de Antígeno L1 de Leucocito/análisis , Saccharomyces cerevisiae/inmunología , Espondiloartritis/diagnóstico , Espondiloartritis/metabolismo , Biomarcadores/análisis , Proteína C-Reactiva/análisis , Espondiloartritis/sangre
2.
Reumatol. clin., Supl. (Barc.) ; 15(supl.1): 26-29, abr. 2019.
Artículo en Español | IBECS | ID: ibc-184212

RESUMEN

Se revisan las distintas técnicas de imagen desde el punto de vista de su utilidad o aplicabilidad como pruebas diagnósticas del desarrollo posterior de daño estructural en pacientes con espondiloartritis. La radiografía simple es la técnica de elección para cuantificar el daño estructural y su progresión. Su inconveniente es que se precisan, al menos, 2 años para detectar cambios y, en el caso de las articulaciones sacroilíacas, la reproducibilidad de las lecturas es baja. La existencia de daño estructural previo se ha asociado con mayor desarrollo de daño estructural futuro, tanto de las articulaciones sacroilíacas como de la columna vertebral. En el caso de la resonancia magnética de articulaciones sacroilíacas, la existencia, extensión e intensidad del edema de médula ósea/osteítis se han asociado con mayor progresión de la sacroilitis. En el caso de la resonancia magnética de columna, el desarrollo y mantenimiento de las lesiones grasas son un factor predisponente para el desarrollo de nuevos sindesmófitos más importante que la existencia de lesiones inflamatorias aisladas. La utilidad de las técnicas de imagen en el pronóstico del daño estructural en la enfermedad periférica está mucho menos establecida


This article reviews the different imaging studies available in terms of their utility or applicability in predicting progression of structural damage in patients with spondyloarthritis. Plain-film radiography is the first choice imaging technique to quantify structural damage and its progression. Its disadvantage is that at least 2 years are required to detect changes and that, in the case of sacroiliac joints, the reproducibility of the X-Ray readings is low. The presence of previous structural damage has been associated with greater development of future structural damage, both in the sacroiliac joints and in the spine. In magnetic resonance imaging of the sacroiliac joints, the extent and intensity of bone marrow oedema/osteitis have been associated with higher progression of sacroiliitis. In magnetic resonance imaging of the spine, the development and persistence of fatty lesions might be a more important predictive factor of the develop ment of new syndesmophytes than the presence of isolated inflammatory lesions. The utility of the imaging techniques in predicting structural damage in peripheral disease is yet less well established


Asunto(s)
Humanos , Espondiloartritis/diagnóstico por imagen , Radiografía/métodos , Espectroscopía de Resonancia Magnética/métodos , Ultrasonografía/métodos , Tomografía Computarizada por Rayos X/métodos , Espondilitis Anquilosante/diagnóstico por imagen , Diagnóstico por Imagen/métodos , Progresión de la Enfermedad , Espondiloartritis/fisiopatología , Espondiloartritis/complicaciones
3.
Reumatol. clín. (Barc.) ; 15(2): 77-83, mar.-abr. 2019. tab, graf
Artículo en Español | IBECS | ID: ibc-184353

RESUMEN

Objetivos: Desarrollar recomendaciones sobre la actividad física y el ejercicio para pacientes con espondiloartritis (EspA) basadas en la opinión de expertos. Métodos: Dos grupos de expertos, uno de fisioterapeutas, rehabilitadores y profesionales de la actividad física y deporte y otro de reumatólogos con interés en EspA, se reunieron para discutir los resultados de grupos focales con pacientes sobre barreras al ejercicio y de una encuesta a reumatólogos sobre ejercicio en EspA. A continuación se redactaron unas recomendaciones preliminares que fueron sometidas a la opinión de los expertos de ambos grupos mediante metodología Delphi a dos rondas. Resultados: Se emitieron 21 recomendaciones que cubren el ejercicio físico, la adaptación al paciente, el modo de dar los mensajes, el manejo del dolor, el tipo de ejercicios indicado y el seguimiento. El grado de acuerdo varía ligeramente entre los grupos de expertos pero en general fue alto. Los ítems discordantes o con poco acuerdo fueron eliminados del consenso. Conclusiones: Se han emitido recomendaciones sobre cuándo y cómo prescribir ejercicio físico y monitorizarlo en pacientes con EspA basadas en la opinión de expertos en espondilitis y en la prescripción de ejercicio. Deberemos confirmar si estas recomendaciones son útiles para la práctica clínica y tienen efecto en los pacientes con EspA atendidos por reumatólogos


Objective: To develop expert-based recommendations on physical activity and exercise for patients with spondyloarthritis (SpA). Methods: Two discussion groups, one of physical therapists, rehabilitation physicians, and professionals of physical activity and sports, and another of rheumatologists interested in SpA, were held to discuss the results of a survey of rheumatologists on exercise and two focus groups with patients on barriers to exercise. Preliminary recommendations were drafted. These were submitted to the opinion of the experts in both groups according to a two round Delphi methodology. Results: Twenty one recommendations covering general aspects of exercise, adaptation to patient, how to deliver messages, pain management, and type of exercise and monitoring were issued. The level of agreement varied slightly between expert groups but it was high overall. Items with poor agreement were removed from the consensus. Conclusions: We present recommendations on when and how to prescribe and monitor exercise in patients with SpA based on the opinion of experts in exercise and in SpA. We must now test whether these recommendations are useful for clinical practice and have an effect on patients with SpA seen by rheumatologists


Asunto(s)
Humanos , Espondiloartritis/terapia , Terapia por Ejercicio/métodos , Dolor Crónico/terapia , Pautas de la Práctica en Medicina , Manejo del Dolor/métodos , Limitación de la Movilidad , Resultado del Tratamiento
4.
Reumatol Clin (Engl Ed) ; 15(6): 360-362, 2019.
Artículo en Inglés, Español | MEDLINE | ID: mdl-29398466

RESUMEN

OBJECTIVE: To assess the relationship between the increase of fecal calprotectin, anti-Saccharomyces cerevisiae antibodies (ASCA) and disease markers in a group of patients with spondyloarthritis. METHODS: We evaluated patients who were at least 18-years-old and met the Assessment in Spondyloarthritis International Society (ASAS) criteria for spondyloarthritis or the New York modified criteria. We analyzed activity criteria, physical function, analytical criteria (human leukocyte antigen [HLA] B27, fecal calprotectin, presence of ASCA, among others) and demographic data. RESULTS: We included 33 patients. All but one patient had normal ASCA values. We found statistical significance in the correlation of calprotectin with C-reactive protein (CRP) but not with other parameters. We also found a relationship between calprotectin levels and nonsteroidal anti-inflammatory drug (NSAID) intake (P=.001). We found no relationship between CRP levels and NSAID use. After discontinuation of NSAIDs for one month, we found no significant differences in calprotectin levels (P=.9). CONCLUSION: Fecal calprotectin is elevated in patients with spondyloarthritis and correlates positively with CRP. Level of fecal calprotectin is not altered by NSAID use. The amount of ASCA present does not change and does not correlate with any clinical parameters in the study population.


Asunto(s)
Anticuerpos Antifúngicos/sangre , Heces/química , Complejo de Antígeno L1 de Leucocito/análisis , Saccharomyces cerevisiae/inmunología , Espondiloartritis/diagnóstico , Espondiloartritis/metabolismo , Adulto , Biomarcadores/análisis , Proteína C-Reactiva/análisis , Humanos , Persona de Mediana Edad , Espondiloartritis/sangre
5.
Reumatol Clin (Engl Ed) ; 15(2): 77-83, 2019.
Artículo en Inglés, Español | MEDLINE | ID: mdl-28807651

RESUMEN

OBJECTIVE: To develop expert-based recommendations on physical activity and exercise for patients with spondyloarthritis (SpA). METHODS: Two discussion groups, one of physical therapists, rehabilitation physicians, and professionals of physical activity and sports, and another of rheumatologists interested in SpA, were held to discuss the results of a survey of rheumatologists on exercise and two focus groups with patients on barriers to exercise. Preliminary recommendations were drafted. These were submitted to the opinion of the experts in both groups according to a two round Delphi methodology. RESULTS: Twenty one recommendations covering general aspects of exercise, adaptation to patient, how to deliver messages, pain management, and type of exercise and monitoring were issued. The level of agreement varied slightly between expert groups but it was high overall. Items with poor agreement were removed from the consensus. CONCLUSIONS: We present recommendations on when and how to prescribe and monitor exercise in patients with SpA based on the opinion of experts in exercise and in SpA. We must now test whether these recommendations are useful for clinical practice and have an effect on patients with SpA seen by rheumatologists.


Asunto(s)
Terapia por Ejercicio/métodos , Espondiloartritis/rehabilitación , Adulto , Testimonio de Experto , Femenino , Grupos Focales , Humanos , Masculino , Persona de Mediana Edad
6.
Reumatol. clín. (Barc.) ; 14(6): 320-333, nov.-dic. 2018. tab, graf
Artículo en Español | IBECS | ID: ibc-176025

RESUMEN

Objetivo: La aparición de nueva información sobre las terapias biológicas en la espondiloartritis axial (EspAax) ha impulsado una nueva revisión de las recomendaciones de la Sociedad Española de Reumatología (SER) basadas en la mejor evidencia posible. Estas nuevas recomendaciones pueden servir de referencia para reumatólogos implicados en el tratamiento de estos pacientes. Métodos: Se creó un panel formado por nueve reumatólogos expertos en EspAax, previamente seleccionados por la SER mediante una convocatoria abierta. Las fases del trabajo fueron: identificación de las áreas clave para la actualización del consenso anterior, análisis y síntesis de la evidencia científica (sistema modificado de Oxford, CEBM, 2009) y formulación de recomendaciones a partir de esta evidencia y de técnicas de consenso. Resultados: Esta revisión de las recomendaciones comporta una actualización en la evaluación de actividad de la enfermedad y objetivos de tratamiento. Incorpora también los nuevos fármacos disponibles, así como sus nuevas indicaciones, y una revisión de los factores predictivos de respuesta terapéutica y progresión del daño radiográfico. Finalmente, estas recomendaciones abordan también las situaciones de fracaso a un primer anti-TNF, así como la posible optimización de la terapia biológica. El documento incluye una tabla de recomendaciones y un algoritmo de tratamiento. Conclusiones: Se presenta la actualización de las recomendaciones SER para el uso de terapias biológicas en pacientes con EspAax


Objective: Recent data published on biological therapy in axial spondyloarthritis (axSpA) since the last publication of the recommendations of the Spanish Society of Rheumatology (SER) has led to the generation of a review of these recommendations based on the best possible evidence. These recommendations should be a reference for rheumatologists and those involved in the treatment of patients with axSpA. Methods: Recommendations were drawn up following a nominal group methodology and based on systematic reviews. The level of evidence and grade of recommendation were classified according to the model proposed by the Centre for Evidence Based Medicine at Oxford. The level of agreement was established through the Delphi technique. Results: In this review, we did an update of the evaluation of disease activity and treatment objectives. We included the new drugs with approved therapeutic indication for axSpA. We reviewed both the predictive factors of the therapeutic response and progression of radiographic damage. Finally, we drafted some recommendations for the treatment of patients refractory to anti-tumor necrosis factor, as well as for the possible optimization of biological therapy. The document also includes a table of recommendations and a treatment algorithm. Conclusions: We present an update of the SER recommendations for the use of biological therapy in patients with axSpA


Asunto(s)
Humanos , Espondiloartritis/tratamiento farmacológico , Terapia Biológica/métodos , Anticuerpos Monoclonales Humanizados/administración & dosificación , Pautas de la Práctica en Medicina/tendencias , Práctica Clínica Basada en la Evidencia/métodos , Progresión de la Enfermedad , Resultado del Tratamiento , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Certolizumab Pegol/administración & dosificación , Interleucina-17/antagonistas & inhibidores
7.
Reumatol Clin (Engl Ed) ; 14(6): 320-333, 2018.
Artículo en Inglés, Español | MEDLINE | ID: mdl-29050839

RESUMEN

OBJECTIVE: Recent data published on biological therapy in axial spondyloarthritis (axSpA) since the last publication of the recommendations of the Spanish Society of Rheumatology (SER) has led to the generation of a review of these recommendations based on the best possible evidence. These recommendations should be a reference for rheumatologists and those involved in the treatment of patients with axSpA. METHODS: Recommendations were drawn up following a nominal group methodology and based on systematic reviews. The level of evidence and grade of recommendation were classified according to the model proposed by the Centre for Evidence Based Medicine at Oxford. The level of agreement was established through the Delphi technique. RESULTS: In this review, we did an update of the evaluation of disease activity and treatment objectives. We included the new drugs with approved therapeutic indication for axSpA. We reviewed both the predictive factors of the therapeutic response and progression of radiographic damage. Finally, we drafted some recommendations for the treatment of patients refractory to anti-tumor necrosis factor, as well as for the possible optimization of biological therapy. The document also includes a table of recommendations and a treatment algorithm. CONCLUSIONS: We present an update of the SER recommendations for the use of biological therapy in patients with axSpA.


Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Terapia Biológica/normas , Espondiloartritis/tratamiento farmacológico , Antirreumáticos/uso terapéutico , Terapia Biológica/métodos , Técnica Delphi , Humanos , España , Espondiloartritis/diagnóstico , Resultado del Tratamiento
12.
Reumatol Clin ; 9(4): 221-5, 2013.
Artículo en Inglés, Español | MEDLINE | ID: mdl-23474378

RESUMEN

OBJECTIVE: To describe the differential characteristics by gender and time since disease onset in patients diagnosed with ankylosing spondylitis (AS) attending the Spanish rheumatology clinics, including those on the "Spanish Registry of spondyloarthritis" (REGISPONSER), as well as the diagnostic and therapeutic implications that this entails. PATIENTS AND METHODS: This is a transversal and observational study of 1514 patients with AS selected from 2367 spondyloarthritis cases included in REGISPONSER. For each patient, the demographics, epidemiology, geriatric, clinical, laboratory, radiological, and therapeutic aspects were were evaluated and comprehensively recorded under the aegis of REGISPONSER, constituting the Minimum Basic identifying data for the disease. Physical function was assessed by Bath Ankylosing Spondylitis Functional Index (BASFI). Clinical activity was evaluated using erythrocyte sedimentation rate, C reactive protein and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Each patient underwent pelvic anteroposterior, anteroposterior and lateral lumbar spine as well as lateral cervical spine x rays; they were scored according to the Bath Ankylosing Spondylitis Spine Radiographic Index, which measures structural damage. RESULTS: Of the 1514 patients screened, 1131 (74.7%) were men. We found significant differences in age at onset of symptoms as well as in the day of inclusion, between the two groups, being lower in men. We also obtained differences in the duration of the disease, which was lower in women. As for the existence of a history of AS among first-degree relatives, family forms were more common among women. The mean BASDAI score was also higher in women, regardless of time since onset of disease. In contrast, the improvement of pain with the use of NSAID's and radiological severity were higher in men, both reaching statistical significance. CONCLUSIONS: Among the Spanish AS patients, there are some differences in the clinical manifestations, even when the time since onset of disease was controlled; we also found radiological differences by gender; men showing more structural damage, while women were more active. These data suggest that the phenotype of AS differs between genders. This can influence the subsequent diagnostic approach and therapeutic decisions.


Asunto(s)
Espondilitis Anquilosante/diagnóstico , Adulto , Estudios Transversales , Femenino , Humanos , Masculino , Persona de Mediana Edad , Factores Sexuales , Factores de Tiempo
13.
Reumatol Clin ; 7(2): 113-23, 2011.
Artículo en Español | MEDLINE | ID: mdl-21794794

RESUMEN

OBJECTIVE: Due to the amount and variability in quality regarding the use of biologic therapy (BT) in patients with spondyloarthritis (SpA), except for psoriatic arthritis (PsA) patients, the Spanish Society of Rheumatology has promoted the generation of recommendations based on the best evidence available. These recommendations should be a reference for rheumatologists and those involved in the treatment of patients with spondyloarthritis (SpA), except for psoriatic arthritis (PsA), who are using, or about to use BT. METHODS: Recommendations were developed following a nominal group methodology and based on systematic reviews. The level of evidence and grade of recommendation were classified according to the model proposed by the Center for Evidence Based Medicine at Oxford. The level of agreement was established through Delphi technique. RESULTS: We have produced recommendations on the use of BT currently available for SpA (but not PsA) in our country. These recommendations include disease assessment, treatment objectives, therapeutic scheme and switching. CONCLUSIONS: We present an update on the SER recommendations for the use of BT in patients with SpA, except for PsA.


Asunto(s)
Terapia Biológica/normas , Espondiloartritis/tratamiento farmacológico , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Adalimumab , Anticuerpos Monoclonales/administración & dosificación , Anticuerpos Monoclonales/efectos adversos , Anticuerpos Monoclonales/uso terapéutico , Anticuerpos Monoclonales Humanizados/administración & dosificación , Anticuerpos Monoclonales Humanizados/efectos adversos , Anticuerpos Monoclonales Humanizados/uso terapéutico , Antirreumáticos/administración & dosificación , Antirreumáticos/uso terapéutico , Terapia Biológica/métodos , Quimioterapia Combinada , Etanercept , Humanos , Inmunoglobulina G/administración & dosificación , Inmunoglobulina G/efectos adversos , Inmunoglobulina G/uso terapéutico , Infliximab , Metotrexato/administración & dosificación , Metotrexato/uso terapéutico , Receptores del Factor de Necrosis Tumoral/administración & dosificación , Receptores del Factor de Necrosis Tumoral/uso terapéutico , Espondiloartritis/clasificación , Sulfasalazina/administración & dosificación , Sulfasalazina/uso terapéutico
14.
Reumatol. clín. (Barc.) ; 7(2): 113-123, mar.-abr. 2011. tab
Artículo en Español | IBECS | ID: ibc-86110

RESUMEN

Objetivo. Dada la gran cantidad de información sobre las terapias biológicas (TB) en las espondiloartritis (EspA), excepto la artritis psoriásica (APs), y la variabilidad en cuanto a su calidad, desde la Sociedad Española de Reumatología (SER) se ha impulsado la generación de recomendaciones basadas en la mejor evidencia posible. Estas deben de servir de referencia para reumatólogos e implicados en el tratamiento de estos pacientes. Métodos. Las recomendaciones se emitieron siguiendo la metodología de grupos nominales. El nivel de evidencia y el grado de recomendación se clasificaron según el modelo del Center for Evidence Based Medicine de Oxford y el grado de acuerdo se extrajo por técnica Delphi. Resultados. Se realizan recomendaciones sobre el uso de las TB para el tratamiento de las EspA (excepto la APs). Incluyen la evaluación de la enfermedad, objetivos del tratamiento, esquema terapéutico y cambios en éste. Conclusiones. Se presentan las actualizaciones a las recomendaciones SER para el uso de TB en pacientes con EsA, excepto la APs(AU)


Objective. Due to the amount and variability in quality regarding the use of biologic therapy (BT) in patients with spondyloarthritis (SpA), except for psoriatic arthritis (PsA) patients, the Spanish Society of Rheumatology has promoted the generation of recommendations based on the best evidence available. These recommendations should be a reference for rheumatologists and those involved in the treatment of patients with spondyloarthritis (SpA), except for psoriatic arthritis (PsA), who are using, or about to use BT. Methods. Recommendations were developed following a nominal group methodology and based on systematic reviews. The level of evidence and grade of recommendation were classified according to the model proposed by the Center for Evidence Based Medicine at Oxford. The level of agreement was established through Delphi technique. Results. We have produced recommendations on the use of BT currently available for SpA (but not PsA) in our country. These recommendations include disease assessment, treatment objectives, therapeutic scheme and switching. Conclusions. We present an update on the SER recommendations for the use of BT in patients with SpA, except for PsA(AU)


Asunto(s)
Humanos , Masculino , Femenino , Conferencias de Consenso como Asunto , Terapia Biológica/métodos , Terapia Biológica , Espondilitis Anquilosante/terapia , Espondiloartritis/terapia , Dolor de la Región Lumbar/epidemiología , Dolor de la Región Lumbar/etiología , Terapia Biológica/estadística & datos numéricos , Terapia Biológica/tendencias , Espondilitis Anquilosante/epidemiología , Espondilitis Anquilosante/prevención & control , Espondilitis Anquilosante/fisiopatología , Dolor de la Región Lumbar/terapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA